Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$60.0 - $68.46 $24.1 Million - $27.5 Million
-401,255 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $7,141 - $8,979
115 Added 0.03%
401,255 $25.4 Million
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $940,420 - $1.09 Million
-13,000 Reduced 3.14%
401,140 $30.9 Million
Q1 2020

May 13, 2020

SELL
$62.63 - $80.22 $6.86 Million - $8.79 Million
-109,535 Reduced 20.92%
414,140 $31 Million
Q4 2019

Feb 13, 2020

BUY
$61.62 - $67.78 $317,343 - $349,067
5,150 Added 0.99%
523,675 $34 Million
Q3 2019

Nov 14, 2019

BUY
$62.51 - $69.0 $125,020 - $138,000
2,000 Added 0.39%
518,525 $32.9 Million
Q2 2019

Aug 13, 2019

BUY
$61.87 - $69.38 $309,040 - $346,553
4,995 Added 0.98%
516,525 $34.9 Million
Q1 2019

May 14, 2019

BUY
$62.53 - $70.05 $298,268 - $334,138
4,770 Added 0.94%
511,530 $33.3 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $817,290 - $1.07 Million
13,500 Added 2.74%
506,760 $31.7 Million
Q3 2018

Nov 14, 2018

BUY
$71.28 - $78.92 $5.19 Million - $5.74 Million
72,745 Added 17.3%
493,260 $38.1 Million
Q2 2018

Aug 14, 2018

SELL
$64.88 - $75.68 $6.79 Million - $7.92 Million
-104,625 Reduced 19.92%
420,515 $29.8 Million
Q1 2018

May 14, 2018

SELL
$72.84 - $88.8 $5.95 Million - $7.26 Million
-81,745 Reduced 13.47%
525,140 $39.6 Million
Q4 2017

Feb 14, 2018

SELL
$71.15 - $83.52 $529,000 - $620,971
-7,435 Reduced 1.21%
606,885 $43.5 Million
Q3 2017

Nov 14, 2017

SELL
$72.11 - $85.47 $16.4 Million - $19.4 Million
-227,135 Reduced 26.99%
614,320 $49.8 Million
Q2 2017

Aug 11, 2017

BUY
N/A
841,455
841,455 $59.6 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nicholas Company, Inc. Portfolio

Follow Nicholas Company, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Company, Inc. with notifications on news.